Infinium Pharmachem Ltd.: overview

On 3rd September, Go India Advisors (GIA) had the privilege to take a group of investors and Analysts to visit Infinium Pharmachem Ltd manufacturing plant in Anand, Gujarat. We had the opportunity to interact with the promoter, senior management and technical personnels, gaining valuable insights from the ones who were running the plant.

Infinium Pharmachem Limited, incorporated in 2003 is a specialised manufacturer of iodine derivatives and Active Pharmaceutical Ingredients (APIs). Over the past two decades, the company has built deep expertise in iodine chemistry, catering to the pharmaceutical, agrochemical, nutraceutical and specialty chemical industries.

Starting with just two iodine-based products potassium iodide and sodium iodide the company has significantly expanded its portfolio and now manufactures 200+ iodine derivatives and 19+ APIs, serving 600+ customers across 45 countries. Its customer base includes several leading Indian and global pharmaceutical companies, such as Neuland, Biocon, Zydus Cadila, Sun Pharma, Torrent, Lupin, Syngene, Hetero and Glenmark and many more.

Visit at a Glance
Unit 1- Sojitra Facility

· Has an installed intermediate manufacturing capacity of 1,800 MTPA

·  The facility houses the complete manufacturing process, from raw-material storage to finished-goods production.

·  The rejection ratio has been effectively zero since 2003, with minor deviations being rectified through process refinement.

·  The facility also has dedicated R&D capabilities for both APIs and intermediates, with separate infrastructure supporting product development.

 

Key Equipment Observed: -

Unit 2: (Contrast Media Project)

· Commercial production is targeted to commence in September 2026, with an installed capacity of 360 MT/annum.

· The facility will manufacture key contrast-media intermediates, primarily Atipa dichloride.

What's Changing: The Two-Pronged Pivot

 

1. Backward integration: Securing the scarce raw material

 

Iodine itself is a naturally scarce, largely imported element for India. It is sourced from only a handful of geographies worldwide chiefly Chile, Japan, and pockets of Turkmenistan, Azerbaijan and the US Gulf Coast/Oklahoma region. This forms a barrier to entry for new players. Infinium has over 2 decades of experience in iodine chemistry. The company leveraged its expertise through its subsidiary Infinium Healthcare Private Limited and has entered a 50:50 US joint venture, IBL Elements Incorporation, targeting iodine extraction from oilfield saltwater brine using proprietary technology capable of 99.9% purity. It targets to deliver 30% of Infinium's ~250–300 MT captive iodine requirement under a 30-year supply agreement.

 

2. Forward integration: Contrast media raw materials

 

The second and more revenue-visible leg is the move into contrast media intermediates, the raw materials used in PET scan, MRI, X-ray, etc. This segment is expected to contribute roughly Rs 60 crore of revenue in second half of the year of FY27, at an industry-benchmarked EBITDA margin of 29–30%. The company expects to cater to customers across India, China, South Korea and the US.

Outlook: The company has delivered 4 year revenue CAGR growth of 18% despite relying on imports for a significant portion of its raw-material requirements. Revenue has grown consistently despite capacity utilisation remaining below 100%. The company has maintained healthy ROCE at 13.04%. Management has guided for steady growth of 15% in the legacy API, intermediate and iodine-derivative businesses. In the second year after commercialisation of the Contrast Media project, management expects the segment to contribute approximately Rs 100 crore of revenue. At a blended company level, management is targeting an EBITDA margin of ~22% by FY28, supported by the higher-margin Contrast Media business and continued growth in the legacy portfolio. Steady demand from existing customers is expected to support further uptake of value-added products in iodine chemistry such as ATIPA. At CMP, the company trades at 35x PE on TTM Basis.

Request for Management Meeting Disclaimer - Informational only. Not investment advice.
GoIndia Advisors LLP | SEBI Registered Research Analyst | Reg. No. INH000020040 | BSE Enlistment No. - 6518